Edesa Biotech, Inc.
NASDAQ:EDSABiotechnology
+$0.09 today
- Market cap
- $55.39M
- Beta
- 1.07
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.27
Volume 0.07M
Average 0.62M
EDSA Tax Payables
Taxes owed to authorities that have not yet been paid.
Edesa Biotech, Inc.NASDAQ: EDSA
Tax Payables · Q2 FY2026 · quarter ended Mar 2026
Tax payables remains negative
Q2 FY2026 tax payables was $0, compared with $0 a year earlier.
Context
- Tax payables amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Tax payables increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Tax Payables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Tax Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 0 | — |
| FY2024 | 2024-09-30 | 0 | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
| FY2021 | 2021-09-30 | 0 | — |
Tax Payables vs competitors
How EDSA compares with its peers on the latest reported figures
- EDSA's Mar 2026 tax payables of $0 is the highest of the 2 companies compared; the peer median is $0.
- Tax payables amounts to 0.0% of total assets for EDSA, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding EDSA) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for EDSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7.84M | 7.09M | 5.36M | 1.04M | 10.79M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 3.3M | 1.26M | 626.54K | 270.91K | 642.87K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 948.65K | 745.54K | 448.91K | 367.39K | 77.84K |
| Total Current Assets | 12.09M | 9.09M | 6.44M | 1.68M | 11.51M |
| Property, Plant & Equipment (Net) | 111.56K | 31.16K | 100.08K | 18.36K | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2.38M | 2.28M | 2.18M | 2.08M | 1.98M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 171.46K | 173.49K | 41.15K | 39.97K |
| Total Non-current Assets | 2.49M | 2.48M | 2.45M | 2.14M | 2.02M |
| Total Assets | 14.58M | 11.58M | 8.89M | 3.81M | 13.53M |
| Account Payables | 1.38M | 2.12M | 1.75M | 1.81M | 0 |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | (2.12M) | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 2.12M | 0 | 0 | 1.08M |
| Total Current Liabilities | 1.46M | 2.14M | 1.82M | 1.83M | 1.08M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 126K | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 47.2K | 43.66K | 0 | 0 | 0 |
| Total Non-current Liabilities | 67.71K | 43.66K | 19.77K | 126K | 0 |
| Total Liabilities | 1.53M | 2.18M | 1.84M | 1.83M | 1.08M |
| Common Stock | 34.89M | 42.47M | 46.64M | 47.24M | 54.52M |
| Retained Earnings | (26.5M) | (44.04M) | (52.42M) | (58.59M) | (65.91M) |
| Accumulated OCI | (205.26K) | (213.6K) | (214.65K) | (242.61K) | (165.77K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 13.06M | 9.39M | 7.05M | 1.98M | 12.45M |
| Total Debt | 99.32K | 18.98K | 94.49K | 19.87K | 0 |
| Net Debt | (7.74M) | (7.07M) | (5.27M) | (1.02M) | (10.79M) |
Edesa Biotech, Inc.
NASDAQ:EDSA
Intrinsic Alpha fair value
Locked
Current Price
$5.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.